Carenostics vs Lucem Health (2026)
Both find patients who already have a disease nobody has diagnosed, and they differ on who owns the model. Carenostics built its own, reading existing record data including unstructured notes to surface undiagnosed chronic disease, founded after a family member died of exactly that. Lucem sells early detection as a programme across several conditions with models developed by partner companies, so the health system buys the operating layer, the outreach and the workflow rather than the algorithm. The programme layer is genuinely the harder part in practice, since a candidate list nobody works is worth nothing. But it concentrates every governance question at a point the health system cannot reach: when accuracy, drift or subgroup performance comes up, the answer belongs to a partner with no contract in the room.
- The model is the company's own rather than licensed, reading existing record data including unstructured notes to find patients who already have a chronic condition nobody has diagnosed.
- It was founded after a family member died of an undiagnosed chronic kidney disease, and the product is built around that single failure rather than around a screening portfolio.
- Owning the model means the accuracy question has one owner rather than routing through to a partner nobody in the room represents.
- It runs early detection as a programme across several conditions, covering lung and colorectal cancer, liver disease, arrhythmias and diabetes progression under one operating model.
- Programme delivery is the harder part in practice, since finding candidates is worthless if nobody runs the outreach and the confirmatory testing, and that is what is being bought.
- For a health system that wants detection across a portfolio rather than one disease, buying the programme layer avoids assembling it per condition.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Carenostics and Lucem Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Carenostics | Lucem Health |
|---|---|---|
| Primary category | Clinical Decision Support | Clinical Decision Support |
| Headquarters | Not recorded | Davidson, North Carolina, United States |
| Website | carenostics.com | lucemhealth.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Carenostics its top capability grade on AI Centrality and Deployment Model and Data Residency. Set against Lucem Health, Carenostics grades higher on several axes, including AI Centrality, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Its thinnest published disclosure sits on several axes, including HIPAA and BAA Posture, Security Certifications and Trust Center and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index records no top capability grade for Lucem Health on any axis it scores. Set against Carenostics, Lucem Health grades higher on Setting and Specialty Coverage. Its thinnest published disclosure sits on several axes, including AI Centrality, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Carenostics or Lucem Health?
On the axes where the AI Health Index separates them, Carenostics grades higher on several axes, including AI Centrality, Model Supply Chain Disclosure and AI Safety and PHI Stewardship, and Lucem Health grades higher on Setting and Specialty Coverage. Carenostics leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Carenostics and Lucem Health differ most?
The widest separation the AI Health Index records between Carenostics and Lucem Health is on AI Centrality, where Carenostics grades A and Lucem Health grades D. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Carenostics and Lucem Health grade the same?
The AI Health Index grades Carenostics and Lucem Health the same on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Carenostics and Lucem Health not disclosed?
At the last review, at least one of Carenostics and Lucem Health published thin or absent detail on several axes, including AI Centrality, HIPAA and BAA Posture and Security Certifications and Trust Center. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The structural difference decides where accountability sits. Lucem's models belong to other companies, so every governance question about accuracy, drift and subgroup performance routes through to a partner the health system has no contract with, and that concentration deserves naming rather than scoring. Neither vendor publishes a retention position, secondary use policy or subgroup analysis.
Case finding also carries a downstream cost neither prices: a surfaced patient generates outreach, a confirmatory test and sometimes a diagnosis the system must then treat, and that burden lands on the provider rather than the vendor.